{
    "clinical_study": {
        "@rank": "152969", 
        "arm_group": [
            {
                "arm_group_label": "K1, LZP, and K2", 
                "arm_group_type": "Active Comparator", 
                "description": "Ketamine 0.41 (K1) followed by lorazepam (LZP) and then ketamine 0.71. Infusions are separated by 48 hours. This ordering allows for comparison between K1 and LZP, and between the post-K1 additive effects of LZP and K2."
            }, 
            {
                "arm_group_label": "LZP, K1, and K2", 
                "arm_group_type": "Active Comparator", 
                "description": "LZP followed by K1 and then K2. Infusions are separated by 48 hours. This order allows for comparison between LZP and K1."
            }, 
            {
                "arm_group_label": "K1, K2, and LZP", 
                "arm_group_type": "Active Comparator", 
                "description": "K1 followed by K2 and then LZP. Infusions are separated by 48 hours. This allows for within-subject comparison of the post-K1 additive effects of K2 and LZP."
            }
        ], 
        "brief_summary": {
            "textblock": "Cocaine dependence involves problematic neuroadaptations, such as heightened reactivity to\n      cocaine cues, that may be responsive to pharmacological modulation of glutamatergic\n      circuits. Despite promising preclinical findings with n-methyl-d-aspartate receptor (NMDAr)\n      modulators, studies with human subjects have been unsuccessful to date. The purpose of this\n      investigation is to examine the effects of the NMDAr antagonist ketamine, recently found to\n      have potent therapeutic effects in humans, on cue-induced craving in cocaine dependent and\n      on impaired motivation for quitting cocaine participants, 24-hours post-infusion."
        }, 
        "brief_title": "Glutamatergic Modulation of Cocaine-related Deficits", 
        "completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "condition": "Cocaine Dependence Related Impairments in Motivation for Change, and in Cue-induced Arousal", 
        "condition_browse": {
            "mesh_term": "Cocaine-Related Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          1. Active free-base cocaine dependence (at least 4 days of use over the past month, with\n             at least 1 use per week); if the participant uses through another route (IN, IV),\n             then the FB route is dominant (> 80% of occasions).\n\n          2. Physically healthy\n\n          3. No adverse reactions to study medications\n\n        4.21-52 years of age\n\n        5.Normal body weight\n\n        6.Responsive to drug cues\n\n        7.Capacity to consent\n\n        Exclusion Criteria:\n\n          1. Seeking treatment or abstinence\n\n          2. DSM IV criteria for substance dependence (other than methamphetamine, cocaine,\n             cannabis, or nicotine), or DSM IV criteria for abuse of ketamine or lorazepam\n\n          3. DSM-IV criteria for other Axis I psychiatric illness that may make participation\n             hazardous such as schizophrenia, schizoaffective disorder, psychosis NOS, MDD,\n             psychosis secondary to substances, or bipolar disorder\n\n          4. Delirium, Dementia, Amnesia, Cognitive Disorders, or dissociative disorders\n\n          5. Current suicide risk or a history of suicide attempt within the past 2 years\n\n          6. Current use of prescribed psychotropic medication\n\n          7. Pregnancy, nursing, or had a baby within the past 6 mo.\n\n          8. Heart disease as indicated by history, abnormal ECG, previous cardiac surgery.\n\n          9. Unstable physical disorders which might make participation hazardous such as\n             end-stage AIDS, hypertension (>140/90), anemia, active hepatitis or other liver\n             disease, or diabetes\n\n         10. \"Bad\" reaction/experience with prior exposure to ketamine or lorazepam\n\n         11. History of significant violence\n\n         12. First degree relative with a psychotic disorder"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "52 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 8, 2013", 
        "id_info": {
            "nct_id": "NCT01790490", 
            "org_study_id": "6162"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "K1, LZP, and K2", 
                    "LZP, K1, and K2", 
                    "K1, K2, and LZP"
                ], 
                "description": "52 minute iv infusion of ketamine 0.41 mg/kg", 
                "intervention_name": "Ketamine 0.41 mg/kg", 
                "intervention_type": "Drug", 
                "other_name": "K1"
            }, 
            {
                "arm_group_label": [
                    "K1, LZP, and K2", 
                    "LZP, K1, and K2", 
                    "K1, K2, and LZP"
                ], 
                "description": "52 minute iv infusion of ketamine 0.71 mg/kg. This dose follows K1 in all 3 orderings.", 
                "intervention_name": "ketamine 0.71 mg/kg", 
                "intervention_type": "Drug", 
                "other_name": "K2"
            }, 
            {
                "arm_group_label": [
                    "K1, LZP, and K2", 
                    "LZP, K1, and K2", 
                    "K1, K2, and LZP"
                ], 
                "description": "52 minute infusion of lorazepam 2 mg. This serves as an active control.", 
                "intervention_name": "lorazepam 2 mg", 
                "intervention_type": "Drug", 
                "other_name": "LZP"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ketamine", 
                "Lorazepam"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "NY", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10032"
                }, 
                "name": "NYSPI"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "other_outcome": [
            {
                "description": "Assesses level of physiological arousal to cues using galvanic skin response", 
                "measure": "Change in Physiological Reactivity", 
                "safety_issue": "No", 
                "time_frame": "change across infusions over 9 days"
            }, 
            {
                "description": "Weekly assessment of cocaine use by urine toxicology and history", 
                "measure": "Cocaine Use in Follow-up", 
                "safety_issue": "No", 
                "time_frame": "4-week follow up"
            }
        ], 
        "overall_official": [
            {
                "affiliation": "NYSPI/Columbia College of Physicians and Surgeons", 
                "last_name": "Elias Dakwar, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "NYSPI/Columbia College of Physicians and Surgeons", 
                "last_name": "Carl Hart, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: National Institute on Drug Abuse"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Serial visual analogue scale (VAS) scores for craving elicited by cocaine cue. Scores are obtained at baseline and at 24 hours after each infusion.", 
                "measure": "Change in Cue Reactivity", 
                "safety_issue": "No", 
                "time_frame": "change across infusions over 9 days"
            }, 
            {
                "description": "Motivation score obtained from the University of Rhode Island Change Assessment (URICA). Scores are obtained at baseline and at 24 hours after each infusion.", 
                "measure": "Change in Motivation", 
                "safety_issue": "No", 
                "time_frame": "Change across infusions over 9 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01790490"
        }, 
        "responsible_party": {
            "investigator_affiliation": "New York State Psychiatric Institute", 
            "investigator_full_name": "Elias Dakwar", 
            "investigator_title": "Assistant Professor Clinical Psychiatry", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Various measures ascertain level of dissociation, abuse liability, and behavioral disturbances.", 
                "measure": "Acute tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "immediately after each infusion over 5 days"
            }, 
            {
                "description": "Weekly assessment of drug use by history and urine toxicology", 
                "measure": "Risk of initiating experimental drug misuse", 
                "safety_issue": "Yes", 
                "time_frame": "4 week follow-up after completion of inpatient phase"
            }
        ], 
        "source": "New York State Psychiatric Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "New York State Psychiatric Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}